Supplement

You have full text access to this OnlineOpen article

Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: The potential role†‡

  1. Mona Saraiya MD, MPH1,§,*,
  2. Marc T. Goodman PhD2,
  3. S. Deblina Datta MD3,
  4. Vivien W. Chen PhD4,
  5. Phyllis A. Wingo PhD5

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23755

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 3047–3057, 15 November 2008

Additional Information

How to Cite

Saraiya, M., Goodman, M. T., Datta, S. D., Chen, V. W. and Wingo, P. A. (2008), Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: The potential role. Cancer, 113: 3047–3057. doi: 10.1002/cncr.23755

Author Information

  1. 1

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  2. 2

    Cancer Research Center, University of Hawaii, Honolulu, Hawaii

  3. 3

    Division of Sexually Transmitted Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

  4. 4

    Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana

  5. 5

    Independent Consultant, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  1. §

    Fax: (770) 488-4693.

*Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, 4770 Buford Highway, Mailstop K-55, Atlanta, GA 30030

  1. †

    Marc Goodman has received support from Public Health Service contract N01-PC-67001 from the Department of Health and Human Services, National Institutes of Health. Phyllis Wingo has received support from the Centers for Disease Control and Prevention for her role as a consultant on this project.The authors thank Mark Sherman, Hannah Weir, Lauri Markowitz, Mark Schiffman, Diane Solomon, Ken Gerlach, and Missy Jamison for reviewing earlier versions of this article.

  2. ‡

    The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 16 JUN 2008
  4. Manuscript Revised: 7 JUN 2008
  5. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (216K)

REFERENCES

  • 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030–3044.
    Direct Link:
  • 2
    Bosch FX,Lorincz A,Munoz N,Meijer CJ,Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244–265.
  • 3
    Clifford G,Franceschi S,Diaz M,Munoz N,Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24( suppl 3): S26–S34.
  • 4
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890–907.
  • 5
    Rousseau MC,Pereira JS,Prado JC,Villa LL,Rohan TE,Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001; 184: 1508–1517.
  • 6
    Liaw KL,Hildesheim A,Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001; 183: 8–15.
  • 7
    Mao C,Koutsky LA,Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107: 18–27.
  • 8
    Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of 4 randomised clinical trials. Lancet. 2007; 369: 1861–1868.
  • 9
    Koutsky LA,Ault KA,Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645–1651.
  • 10
    Pan American Health Organization (PAHO), Immunization Unit. Ad hoc meeting of experts on surveillance of HPV-associated diseases in the americas. PAHO Immunization Newsletter. December 2006: 1–4.
  • 11
    US Cancer Statistics Working Group. United States Cancer Statistics 1999-2003 Incidence and Mortality Web-based Report. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007.
  • 12
    Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomavirus [90]. Lyon, France: International Agency for Research on Cancer; 2007.
  • 13
    Dillner J,Arbyn M,Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2007; 148: 199–207.
    Direct Link:
  • 14
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467–475.
  • 15
    Ryerson AB,Peters ES,Coughlin SS, et al. Burden of potentially HPV-associated cancers of the oropharynx and oral cavity in the United States, 1998-2003. Cancer. 2008; 113( suppl 6): 000–000.
  • 16
    Sturgis EM,Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007; 110: 1429–1435.
    Direct Link:
  • 17
    American Association of Cancer Registries, Data Standards Committee. Subcommittee on Noninvasive Cervix Lesions, Working Group on Preinvasive Cervical Cancer Neoplasia and Population-based Cancer Registries: Final Subcommittee Report Rockville, MD, April 5-6, 1993.
  • 18
    HavenerLA,HultstromD, eds. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Eleventh Edition, Version 11.1. Springfield, Ill: North American Association of Central Cancer Registries; 2006. Available at: http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf. Accessed on July 16, 2008.
  • 19
    Sherman ME,Lorincz AT,Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 46–52.
  • 20
    Carreon JD,Sherman ME,Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26: 441–446.
  • 21
    Bosch FX,Manos MM,Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796–802.
  • 22
    Cox JT,Schiffman M,Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003; 188: 1406–1412.
  • 23
    Zuna RE,Allen RA,Moore WE,Mattu R,Dunn ST. Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. Mod Pathol. 2004; 17: 1314–1322.
  • 24
    Wright TC,Kurman RJ,Ferenczy A. Precancerous lesions of the cervix. In: KurmanRJ, ed. Blaustein's Pathology of the Female Genital Tract,5th ed. New York, NY: Springer- Verlag; 2001: 253–324.
  • 25
    Copeland G,Datta SD,Spivak G,Garvin AD,Cote ML. Total burden and incidence of in situ and invasive cervix cancer in Michigan, 1985-2003. Cancer. 2008; 113( 10 suppl): 2946–2954.
    Direct Link:
  • 26
    Goodman MT,Hernandez BY,Hewitt S, et al. Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol. 2005; 36: 812–820.
  • 27
    Linkins RW. Immunization registries: progress and challenges in reaching the 2010 national objective. J Public Health Manag Pract. 2001; 7: 67–74.
  • 28
    National Vaccine Advisory Committee. Development of Community and State-based Immunization Registries: Report of the National Vaccine Advisory Committee (NVAC). Atlanta, Ga: US Department of Health and Human Services, CDC; 1999.
  • 29
    Castle PE,Solomon D,Saslow D,Schiffman M. Commentary: predicting the effect of successful human papillomavirus vaccination on existing cervical screening programs in the United States. Cancer. 2008; 113( 10 suppl): 3031–3035.
    Direct Link:
  • 30
    Mayrand MH,Duarte-Franco E,Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579–1588.
  • 31
    Khan MJ,Castle PE,Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 1072–1079.
  • 32
    Goldie SJ,Kim JJ,Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619–631.
  • 33
    Goldie SJ,Kohli M,Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604–615.
  • 34
    Tiro JA,Saraiya M,Jain N, et al. Human papillomavirus and cervical cancer behavioral surveillance in the United States. Cancer. 2008; 113( 10 suppl): 3013–3030.
    Direct Link:
  • 35
    Centers for Disease Control and Prevention, National Cancer Institute. State Cancer Profiles. Bethesda, Md: National Cancer Institute; 2007. Available at: http://statecancerprofiles.cancer.gov/. Accessed on July 16, 2008.
  • 36
    Lehtinen M,Herrero R,Mayaud P, et al. Chapter 28: studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine. 2006; 24( suppl 3): S233–S241.
  • 37
    Wright TCJr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007; 11: 223–239.
View Full Article (HTML) Get PDF (216K)